Retinal imaging for neurological diseases: "a window into the brain"

Sidra Zafar; Joseph McCormick; Luca Giancardo; Shiv Saidha; Alison Abraham; Roomasa Channa

doi:10.1097/IIO.0000000000000261

Retinal imaging for neurological diseases: "a window into the brain"

Sidra Zafar, Joseph McCormick, Luca Giancardo, Shiv Saidha, Alison Abraham, Roomasa Channa

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	137-154
Number of pages	18
Journal	International ophthalmology clinics
Volume	59
Issue number	1
DOIs	https://doi.org/10.1097/IIO.0000000000000261
State	Published - Dec 1 2019

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1097/IIO.0000000000000261

Cite this

@article{0fa1659b637349469450bbc2b59a503f,

title = "Retinal imaging for neurological diseases: {"}a window into the brain{"}",

author = "Sidra Zafar and Joseph McCormick and Luca Giancardo and Shiv Saidha and Alison Abraham and Roomasa Channa",

note = "Funding Information: patients with AD.29,38 Retinal vascular density on OCT-A was found to be significantly decreased whereas foveal avascular zone was significantly enlarged among 26 patients with AD, compared with 26 age-matched controls. Eye Determinants of Cognition Study (EyeDOC) is an ongoing prospective study funded by the National Institute of Aging and nested within the ARIC cohort Neurocognitive Study (ARIC-NS). It aims to assess the association of OCT and OCT-A derived parameters, with patterns of cognitive impairment in a projected sample of 1000 biracial participants (50% white, 50% African American), aged 75 to 94 years. This study is enrolling participants from the original ARIC study who have a mini-mental status examination score of better than 22 for African Americans participants or 24 for white participants to adjust for racial differences. It will assess the potential of OCT and OCT-A not only as potential screening markers for cognitive impairment but also to potentially determine the pathophysiology (vascular damage on OCT-A or neural retinal tissue damage on OCT) of cognitive impairment. Funding Information: S.S.: has received consulting fees from Medical Logix for the development of CME programs in neurology and has served on scientific advisory boards for Biogen-Idec, Genzyme, Genentech Corporation, EMD Serono & Novartis. He is the PI of investigator-initiated studies funded by Genentech Corporation and Biogen Idec, and received support from the Race to Erase MS foundation. He has received equity compensation for consulting from JuneBrain LLC, a retinal imaging device developer. He is also the site investigator of a trial sponsored by MedDay Pharmaceuticals. The remaining authors have nothing to disclose. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",

year = "2019",

month = dec,

day = "1",

doi = "10.1097/IIO.0000000000000261",

language = "English (US)",

volume = "59",

pages = "137--154",

journal = "International Ophthalmology Clinics",

issn = "0020-8167",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - Retinal imaging for neurological diseases

T2 - "a window into the brain"

AU - Zafar, Sidra

AU - McCormick, Joseph

AU - Giancardo, Luca

AU - Saidha, Shiv

AU - Abraham, Alison

AU - Channa, Roomasa

N1 - Funding Information: patients with AD.29,38 Retinal vascular density on OCT-A was found to be significantly decreased whereas foveal avascular zone was significantly enlarged among 26 patients with AD, compared with 26 age-matched controls. Eye Determinants of Cognition Study (EyeDOC) is an ongoing prospective study funded by the National Institute of Aging and nested within the ARIC cohort Neurocognitive Study (ARIC-NS). It aims to assess the association of OCT and OCT-A derived parameters, with patterns of cognitive impairment in a projected sample of 1000 biracial participants (50% white, 50% African American), aged 75 to 94 years. This study is enrolling participants from the original ARIC study who have a mini-mental status examination score of better than 22 for African Americans participants or 24 for white participants to adjust for racial differences. It will assess the potential of OCT and OCT-A not only as potential screening markers for cognitive impairment but also to potentially determine the pathophysiology (vascular damage on OCT-A or neural retinal tissue damage on OCT) of cognitive impairment. Funding Information: S.S.: has received consulting fees from Medical Logix for the development of CME programs in neurology and has served on scientific advisory boards for Biogen-Idec, Genzyme, Genentech Corporation, EMD Serono & Novartis. He is the PI of investigator-initiated studies funded by Genentech Corporation and Biogen Idec, and received support from the Race to Erase MS foundation. He has received equity compensation for consulting from JuneBrain LLC, a retinal imaging device developer. He is also the site investigator of a trial sponsored by MedDay Pharmaceuticals. The remaining authors have nothing to disclose. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.

PY - 2019/12/1

Y1 - 2019/12/1

UR - http://www.scopus.com/inward/record.url?scp=85059125240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059125240&partnerID=8YFLogxK

U2 - 10.1097/IIO.0000000000000261

DO - 10.1097/IIO.0000000000000261

M3 - Article

C2 - 30585923

AN - SCOPUS:85059125240

VL - 59

SP - 137

EP - 154

JO - International Ophthalmology Clinics

JF - International Ophthalmology Clinics

SN - 0020-8167

IS - 1

ER -

Retinal imaging for neurological diseases: "a window into the brain"

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this